Class / Patent application number | Description | Number of patent applications / Date published |
424434000 | Mucosal (e.g., nasal, etc.) | 46 |
20080220050 | Compositions For Gingival Retraction And Other Methods - At least one clay, at least one glass filler, and at least one astringent agent are formulated with water into a paste for injection in dental and medical applications. In one embodiment, the paste is used to treat and/or widen a gingival sulcus. The paste is readily rinsed off the surface to which it is applied using water. | 09-11-2008 |
20080305149 | Mucoadhesive vesicles for drug delivery - Vesicles for delivery of active macromolecules which are formed from amphiphilic segmented copolymers having one or more mucoadhesive groups or regions and which can be used for delivery of an active agent to an area of the body having a mucous membrane, such as but not limited to the gastrointestinal tract. | 12-11-2008 |
20090028923 | Implantable Devices and Methods for Treating Sinusitis and Other Disorders - Devices, systems and methods for stenting, spacing, draining, ventilating and/or delivering drugs and other therapeutic or diagnostic substances to desired locations within the bodies of human or non-human animal subjects, including methods and systems for treating paranasal sinusitis and ethmoid disease. | 01-29-2009 |
20090047326 | SINUS DELIVERY OF SUSTAINED RELEASE THERAPEUTICS - The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers. | 02-19-2009 |
20090047327 | SINUS DELIVERY OF SUSTAINED RELEASE THERAPEUTICS - The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers. | 02-19-2009 |
20090238859 | SINUS DELIVERY OF SUSTAINED RELEASE THERAPEUTICS - The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers. | 09-24-2009 |
20100003308 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES - The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components. | 01-07-2010 |
20100055152 | ANTIHISTAMINE AND ANTIHISTAMINE-LIKE NASAL APPLICATION, PRODUCTS, AND METHOD - A method of and product for reducing the undesirable effects of allergic rhinitis by applying a formulation to a person's nasal region or nostrils. The formulation creates a barrier that prevents airborne allergens from contacting nasal mucous membranes, and at the same time, electrostatically repels or attracts and captures the particulate allergens, and changes their shapes so as to mitigate the effects of allergic rhinitis. The formulation may be made more effective by the addition of an anti-histamine compound. | 03-04-2010 |
20130052251 | COMPOSITION AND METHOD FOR TREATING NOSEBLEEDS - A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally. | 02-28-2013 |
20130344127 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES - The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components. | 12-26-2013 |
20140079755 | SELF-EXPANDING DEVICES AND METHODS THEREFOR - Described here are delivery devices for delivering one or more implants to the body, and methods of using. The delivery devices may deliver implants to a variety of locations within the body, for a number of different uses. In some variations, the delivery devices have a cannula with one or more curved sections. In some variations, a pusher may be used to release one or more implants from the cannula. In some variations, one or more of the released implants may be a self-expanding device. Methods of delivering implants to one or more sinus cavities are also described here. | 03-20-2014 |
424435000 | Mouth | 26 |
20080233174 | HIGH DOSE FILM COMPOSITIONS AND METHODS OF PREPARATION - This invention relates to films incorporating high amounts of pharmaceutical agents and methods for the preparation of the same. Moreover, the invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. | 09-25-2008 |
20080268023 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain - Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed. | 10-30-2008 |
20090028924 | USE OF A POLYSACCHARIDE WHICH IS EXCRETED BY THE VIBRIO DIABOLICUS SPECIES FOR THE REGENERATION AND PROTECTION OF THE PERIODONTIUM - The invention relates to the use of a polysaccharide which is excreted by the | 01-29-2009 |
20090104250 | Medical or veterinary digestive tract utilization systems and methods - Systems and methods are described for implementing or deploying medical or veterinary utility modules (a) operable for mooring at least partly within a digestive tract, (b) small enough to pass through the tract per vias naturales and including a wireless-control component, (c) having one or more attachment protrusions positionable adjacent to a mucous membrane, (d) configured to facilitate redundant modes of attachment, (e) facilitating a “primary” material supply deployable within a stomach for an extended and/or controllable period, (f) moored by one or more adaptable extender modules supported by a subject's head or neck, and/or (g) configured to facilitate supporting at least a sensor within a subject's body lumen for up to a day or more. | 04-23-2009 |
20090110714 | Medical or veterinary digestive tract utilization systems and methods - Systems and methods are described for implementing or deploying medical or veterinary utility modules comprising a first module operable in a digestive or respiratory tract to engage a second module, optionally by a magnetic field. Alternatively or additionally, systems may be operable to remain in situ and also operable to permit a therapeutic material dispensation. In some contexts, for example, systems or methods may dispense a therapeutic material via a subject's throat or elsewhere in the digestive or respiratory tract. | 04-30-2009 |
20090130177 | DENTAL IMPLANT AND PRODUCTION METHOD FOR SAID IMPLANT - The invention relates to a dental implant, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterised in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component. The invention also relates to a method for producing a dental implant of this type and to a specific composition, which can be used to produce a coating of this type. | 05-21-2009 |
20090148500 | MEDICINAL IMPLANT CARTRIDGE - The invention includes a cartridge for use in a device for inserting a medicament within a body cavity of a mammal, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen having a uniform cross-section sized to contain the medicament therein, a substantially stationary member disposed within the lumen of the retractable chamber and having a uniform cross-section sized to provide a sliding fit within the lumen suitable to provide for retraction of the retractable chamber about the substantially stationary member upon actuation of the device; and means for retracting the retractable chamber about the substantially stationary member while maintaining the substantially stationary member in a substantially stationary position upon actuation of the device. | 06-11-2009 |
20090175925 | PASSIVE TIME RELEASED SOLUTE TREATMENT - Devices and methods for delivery of a solute to increase blood sugar levels between certain hours in a form that allows for gradual delivery. One variation includes devices and methods for the timed release of a solute of carbohydrate, typically dextrose. | 07-09-2009 |
20100092543 | Dimpled adhering troche for use on teeth or orthodontic braces - A dissolving oral adhering disc with a dimple on at least one side to improve adhesion to hard convex surfaces in the mouth, including teeth, orthodontic braces, and gums (keratinized gingiva). The disc may be designed to prevent or treat a sore in the mouth opposite a tooth or brace and/or to release a medication into the mouth, to treat such as sore or to treat or prevent conditions elsewhere in the mouth or throat or stomach with the medication may be a form a glycyrrhetinic acid that is soluble in water at human mouth temperatures. | 04-15-2010 |
20100098746 | COMPOSITIONS AND METHODS FOR TREATING PERIODONTAL DISEASE COMPRISING CLONIDINE, SULINDAC AND/OR FLUOCINOLONE - Effective treatments of periodontal disease for extended periods of time are provided. Through the administration of an effective amount of clonidine, sulindac, and/or fluocinolone at or near a target site, one can reduce, prevent, and/or treat periodontal disease. In some embodiments, when appropriate formulations are provided within biodegradable polymers, treatment can be continued for at least two weeks to two months. | 04-22-2010 |
20100150985 | Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making the Same - Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject. | 06-17-2010 |
20100172956 | DISSOLVING STRIP FOR ORAL MUCOSA AS A SYSTEMIC DRUG DELIVERY ROUTE - The invention relates to a dissolving strip for drug delivery providing a generally inert water soluble base material attached to the maxillary molars in order to deliver a therapeutic material upon activation by the parotid and other oral salivary glands. The composition of the dissolving strip is a generally inert base material, such as pullulan. The pullulan is impregnated with a therapeutic material to form a solid mixture to carry the therapeutic agent. The dissolving strip has sufficient flexibility to adhere to the 1-4 maxillary molars and acts as a reservoir to deliver therapeutic agents, such as an anti-smoking formula, a diet formula, a sexual enhancement formula, an oral freshness formula, prescription drugs, non-prescription drugs, herbs, or vitamins, or any combination of the previously listed. The dissolving strip is capable of delivering the therapeutic agents in a sustained or time released fashion. | 07-08-2010 |
20100203105 | METHOD FOR ADMINISTERING INSULIN TO THE BUCCAL REGION - A mixed micellar pharmaceutical formulation includes a micellar pharmaceutical agent, an alkali metal C8 to C22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compound. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening primrose oil, trihydroxy oxo cholanyiglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. Each absorption enhancing compound is present in a concentration of from 1 to 10 wt:/wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation. Methods for administering insulin and heparin to the buccal region are also disclosed. | 08-12-2010 |
20100285098 | ADHERING TROCHES WITH SANTACID FOR TREATMENT OF THROAT ESOPHAGUS AND STOMACH - A method for combating unwanted conditions downstream of the mouth with adhering troches. A method to treat or reduce replication of a virus in throat tissues by releasing an anti-viral from an adhering disc. A method to treat sore throat with time release of Glycyrrhiza extract or collagen from an adhering disc. A method to treat sore throat with topically applied cobalamin. An adhering troche that releases antacid, alginate, bismuth subsalicylate, soluble zinc, such as zinc gluconate, bioactive vitamin B12 (methylcobalamin), antibiotic, or anti-viral. A method to combat bacterial effects downstream of the mouth with topically applied xylitol. | 11-11-2010 |
20120015021 | ANTI-APPETITE ADHESIVE COMPOSITIONS - Compositions for appetite suppression and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a tablet, such as a single or multi-layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. In a preferred embodiment, the compositions contain herbal agents that are anti-appetite agents. The composition is generally effective for suppressing appetite for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa. | 01-19-2012 |
20130156842 | BIOADHESIVE DRUG FORMULATIONS FOR ORAL TRANSMUCOSAL DELIVERY - Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same. | 06-20-2013 |
20130189343 | Transmucosal administration system for a pharmaceutical drug - The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route. | 07-25-2013 |
20130323296 | CARRIER FOR OROMUCOSAL, ESPECIALLY SUBLINGUAL ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE SUBSTANCES - The present disclosure relates to a carrier for oromucosal, especially sublingual administration of physiologically active substances, especially of medicinal drugs, which consists of at least one elastic layer ( | 12-05-2013 |
20140271781 | HYDROGEL COMPOSITIONS WITH AN ERODIBLE BACKING MEMBER - A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed. | 09-18-2014 |
20150056268 | UNIFORM FILMS FOR RAPID-DISSOLVE DOSAGE FORM INCORPORATING ANTI-TACKING COMPOSITIONS - The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent. | 02-26-2015 |
20150290122 | METHOD OF ORALLY ADMINISTERING A TREATING AGENT OVER AN EXTENDED PERIOD - An implantation device for and method of orally administering a time released treating agent to a user over an extended period, including fixedly engaging at least one tooth of the user with the agent, and releasing the agent within the oral cavity, so as to be locally or systemically delivered to a remainder portion of the user separate from the teeth over the period. | 10-15-2015 |
20150366793 | TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE - The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment. | 12-24-2015 |
20160166737 | COLLAGEN SPONGE | 06-16-2016 |
20170231977 | MULTIDIRECTIONAL MUCOSAL DELIVERY DEVICES AND METHODS OF USE | 08-17-2017 |
20190142742 | PACKAGE, SYSTEM AND METHODS FOR CUSTODY AND CONTROL OF DRUGS | 05-16-2019 |
20190142743 | METHOD AND COMPOSITION FOR MAKING AN ORAL SOLUBLE FILM, CONTAINING AT LEAST ONE ACTIVE AGENT | 05-16-2019 |
424436000 | Anal, rectal (e.g., suppositories, etc.) | 9 |
20080213339 | Pharmaceutical Composition Containing Indometacin and/or Acemetacin - The invention relates to a pharmaceutically active composition or pharmaceutical form of administering that contains at least one of the active ingredients indomethacin or acemetacin and optionally other adjuvants, the composition containing the active ingredient, or a mixture of the active ingredients, in micronized form, preferably mixed with at least one flavonoid derivative or a polypeptide or with a mixture of such compounds. | 09-04-2008 |
20080274162 | Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository - This invention is a probiotic composition using the delivery mode of a rectal suppository for the treatment and relief of symptoms of urogenital infections including prostatitis. This invention is unique in both mode of delivery and in enabling the treatment of such urogenital infections as prostatitis. The present invention discloses compositions, methodologies, and delivery mode for the utilization of probiotic organisms in therapeutic compositions for treatment and relief from the symptoms of urogenital infections by maintaining and restoring normal flora in humans. The composition includes one or more bacteria selected from the genus | 11-06-2008 |
20090035354 | Device and Method for Treating the Anal Sphincter - A rectally insertable device for localized drug delivery to the anal sphincter of a subject, a method of using the device and the use of the device is disclosed. The device comprises a shell for containing an active pharmaceutical ingredient, the shell being substantially impermeable to the active pharmaceutical ingredient wherein a lower portion of the shell is configured to release the active pharmaceutical ingredient from the shell and wherein when the device is inserted into the rectum of the subject, the lower portion of the shell is proximal to the anal sphincter, such that the active pharmaceutical ingredient is released proximal to the anal sphincter. | 02-05-2009 |
20090041829 | PHARMACEUTICAL DOSAGE FORMS COMPRISING A LIPID PHASE - A tablet for oral administration comprises a lipid phase, comprised to 80% by weight or more by a mixture of (a) triglyceride, (b) mono- or/and diglyceride, and (c) cell membrane lipid; (d) one or more pharmacologically active agents dissolved or dispersed in the lipid phase; (e) water and/or ethanol; and (f) an absorption controlling amount of particulate pharmaceutical excipient. Also disclosed are granules, a suppository for rectal administration, and a capsule filled with the granules. Methods for preparing the tablet, the suppository and the granules are also disclosed as well as uses of the granules and a method for coating them. | 02-12-2009 |
20110008410 | PHARMACEUTICAL COMPOSITION FOR TREATING MALARIA - The invention relates to a pharmaceutical composition in the form of rectal capsules, comprising a combination, effective against malaria parasites, of artemisinine or a derivative of artemisinine, particularly artesunate, with piperaquine or a pharmaceutically acceptable salt thereof, particularly piperaquine tetraphosphate, and having high activity against | 01-13-2011 |
20160175270 | RECTAL SUPPOSITORY FOR ULCERATIVE COLITIS | 06-23-2016 |
20160175271 | RECTAL SUPPOSITORY FOR ULCERATIVE COLITIS | 06-23-2016 |
20160175329 | MESALAMINE SUPPOSITORY | 06-23-2016 |
20160375068 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of | 12-29-2016 |